Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has diagnosis of chronic plaque psoriasis for at least 6 months before the baseline visit.~* Participant meets following disease activity criteria:~* Stable moderate to severe chronic plaque psoriasis, defined as greater than or equal to 10% body surface area (BSA) psoriasis involvement, static physician global assessment (sPGA) score of greater than or equal to 3, and Psoriasis Area Severity Index (PASI) greater than or equal to 12 at Screening and baseline visit.~* Candidate for systemic therapy as assessed by the investigator.~Exclusion Criteria:~* Participant has history of active skin disease other than psoriasis that could interfere with the assessment of psoriasis.~* Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis.~* Participant has previous exposure to risankizumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Risankizumab (Type: EXPERIMENTAL): Subcutaneous (SC), self-administered 150 mg doses of risankizumab at Weeks 0, 4, and 16
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous (SC), self-administered doses of placebo solution at Weeks 0, 4, and 16

Based on this trial design, predict the completion outcome and termination type (if applicable).